Maegim한국어

바이오에프디엔씨

251120KOSDAQSector: Pharma & Biotech
₩8,000▼ 2.56%Market cap ₩69.6BAs of Jul 21, 2026 close · updated once daily
A
Grade A78.9 ptsTop 2% of 2,523 stocks
Financial strength
92.9
Growth momentum
65.7
Price attractiveness
72.4

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

92.9
How much debt does it carry relative to equity?
Debt-to-equity ratio
5.2%
✓ Above median · Top 4.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
1706.2%
✓ Above median · Top 7.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
32.6%
✓ Above median · Top 3.5% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
9.6%
✓ Above median · Top 13.2% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

65.7
How much did revenue grow in a year?
Revenue growth (YoY)
19.4%
✓ Above median · Top 24% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
6.5%
✓ Above median · Top 44.8% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
28.9%
✓ Above median · Top 30.1% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
28.1%
✓ Above median · Top 38.4% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

72.4
Is the price expensive relative to earnings?
P/E (price-to-earnings)
10.4x
✓ Above median · Top 14.8% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
1.00x
✓ Above median · Top 40.4% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15